Drinking from the fountain of promise: Biomarkers in the surveillance of Barrett's oesophagus - The glass is half full!

Gut

Volumn 55, Issue 10, 2006, Pages 1377-1379

  Preston, S L ^a,b   Jankowski, J A ^b,c,d  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53;

BARRETT ESOPHAGUS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; DRINKING; DYSPLASIA; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; METAPLASIA; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VALIDATION PROCESS;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749185735     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.096461     Document Type: Review

References (28)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
2. Prach AT, MacDonald TA, Hopwood DA, et al. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997;350:933.
3. Falk GW. Barrett's esophagus. Gastroenterology 2002;122:1569-91.
4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
5. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
6. Bond JH. Clinical evidence for the adenomacarcinoma sequence, and the management of patients with colorectal adenomas. Semin Gastrointest Dis 2000;11:176-84.
7. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81.
8. Jankowski J, Moayyedi P. Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004;96:885-7.
9. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001;32:379-88.
10. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
11. Murray L, Sedo A, Scott M, et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006;55:1390-7.
12. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunonistochemical study with clinicopathologic correlations. Cancer 1997;79:425-32.
13. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
14. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310-30.
15. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
16. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
17. Prevo LJ, Sanchez CA, Galipeau PC, et al. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
18. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
19. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma Cancer Res 2000;60:5021-6.
20. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
21. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
22. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1990;5:457-9.
23. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-19.
24. Fennerty MB, Sampliner RE, Way D, et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97:815-20.
25. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
26. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.
27. Cawley HM, Meltzer SJ, De Benedetti VM, et al. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998;115:19-27.
28. Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 2006;3:101-11.